Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in advanced hepatocellular carcinoma
NCT03062358Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2017
- Primary completion
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
A Phase 3 trial of pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Merck & Co.. Started Apr 2017; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03062358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03062358.